Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Oct. 6, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial. Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19...

Click to view original post